Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Radiology
Erschienen in: European Radiology 6/2020

16.02.2020 | Gastrointestinal

Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic background

verfasst von: Azusa Kitao, Osamu Matsui, Norihide Yoneda, Kazuto Kozaka, Satoshi Kobayashi, Wataru Koda, Dai Inoue, Takahiro Ogi, Kotaro Yoshida, Toshifumi Gabata

Erschienen in: European Radiology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Gadoxetic acid-enhanced magnetic resonance imaging (MRI) plays important roles in diagnosis of hepatic lesions because of its superiority in the detectability of small lesions, its differentiation ability, and its utility for the early diagnosis of hepatocellular carcinoma (HCC). In HCC, expression of organic anion transporting polypeptide (OATP) 1B3 correlates with the enhancement ratio in the hepatobiliary phase. Gadoxetic acid-enhanced MRI, an indirect molecular imaging method, reflects OATP1B3 expression in HCC. OATP1B3 expression gradually decreases from the dysplastic nodule stage to advanced HCC. Decreased expression is a sensitive marker of multistep hepatocarcinogenesis, especially in the early stages. Hypervascular HCCs commonly show hypointensity in the hepatobiliary phase corresponding to a decrease in OATP1B3; however, approximately 10% of HCCs show hyperintensity due to OATP1B3 overexpression. This hyperintense HCC shows less aggressive biological features and has a better prognosis than hypointense HCC. Hyperintense HCC can be classified into a genetic subtype of HCC with a mature hepatocyte-like molecular expression. OATP1B3 expression and the less aggressive nature of hyperintense HCC are regulated by the molecular interaction of β-catenin signaling and hepatocyte nuclear factor 4α, a tumor suppressor factor. Gadoxetic acid-enhanced MR imaging has the potential to be an imaging biomarker for HCC.

Key Points

• The hepatobiliary phase is a sensitive indirect indicator of organic anion transporting polypeptide1B3 (OATP1B3) expression in hepatocellular carcinoma (HCC).
• The OATP1B3 expression, namely, enhancement in the hepatobiliary phase, decreases from the very early stage of hepatocarcinogenesis, contributing to early diagnosis of HCC.
• HCC showing hyperintensity on the hepatobiliary phase is a peculiar genetic subtype of HCC with OATP1B3 overexpression, a less aggressive nature, and mature hepatocyte-like molecular/genetic features.
Literatur
1.
Hamm B, Staks T, Muhler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792PubMed
2.
Vogl TJ, Kummel S, Hammerstingl R et al (1996) Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200:59–67PubMed
3.
Reimer P, Rummeny EJ, Daldrup HE et al (1997) Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol 7:275–280PubMed
4.
Huppertz A, Haraida S, Kraus A et al (2005) Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT—initial observations. Radiology 234:468–478PubMed
5.
Huppertz A, Balzer T, Blakeborough A et al (2004) Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 230:266–275PubMed
6.
Park G, Kim YK, Kim CS, Yu HC, Hwang SB (2010) Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol 83:1010–1016PubMedPubMedCentral
7.
Besa C, Kakite S, Cooper N, Facciuto M, Taouli B (2015) Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T. Acta Radiol Open 4:2047981614561285PubMedPubMedCentral
8.
Di Martino M, Marin D, Guerrisi A et al (2010) Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 256:806–816PubMed
9.
Sano K, Ichikawa T, Motosugi U et al (2011) Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 261:834–844PubMed
10.
11.
The International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49:658–664
12.
Kitao A, Matsui O, Yoneda N et al (2011) The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 21:2056–2066PubMed
13.
Kogita S, Imai Y, Okada M et al (2010) Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 20:2405–2413PubMed
14.
Channual S, Tan N, Siripongsakun S, Lassman C, Lu DS, Raman SS (2015) Gadoxetate disodium-enhanced MRI to differentiate dysplastic nodules and grade of hepatocellular carcinoma: correlation with histopathology. AJR Am J Roentgenol 205:546–553PubMed
15.
Narita M, Hatano E, Arizono S et al (2009) Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 44:793–798PubMed
16.
Tsuboyama T, Onishi H, Kim T et al (2010) Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging—correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255:824–833PubMed
17.
Kitao A, Zen Y, Matsui O et al (2010) Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging—correlation with molecular transporters and histopathologic features. Radiology 256:817–826PubMed
18.
Lee SA, Lee CH, Jung WY et al (2011) Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI: initial experience. Magn Reson Imaging 29:83–90PubMed
19.
Ueno A, Masugi Y, Yamazaki K et al (2014) OATP1B3 expression is strongly associated with Wnt/beta-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol 61:1080–1087PubMed
20.
Miura T, Ban D, Tanaka S et al (2015) Distinct clinicopathological phenotype of hepatocellular carcinoma with ethoxybenzyl-magnetic resonance imaging hyperintensity: association with gene expression signature. Am J Surg 210:561–569PubMed
21.
Kitao A, Matsui O, Yoneda N et al (2012) Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology 265:780–789PubMedPubMedCentral
22.
Yamashita T, Kitao A, Matsui O et al (2014) Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology 60:1674–1685PubMedPubMedCentral
23.
Choi JW, Lee JM, Kim SJ et al (2013) Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR images and their value as an imaging biomarker. Radiology 267:776–786PubMed
24.
European Society of Radilogy (ESR) (2013) ESR statement on the stepwise development of imaging biomarkers. Insights Imaging 4:147–152
25.
Motosugi U, Ichikawa T, Sou H et al (2009) Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI). J Magn Reson Imaging 30:849–854PubMed
26.
Motosugi U, Ichikawa T, Sano K et al (2011) Double-dose gadoxetic acid-enhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol 46:141–145PubMed
27.
Haradome H, Grazioli L, Tsunoo M et al (2010) Can MR fluoroscopic triggering technique and slow rate injection provide appropriate arterial phase images with reducing artifacts on gadoxetic acid-DTPA (Gd-EOB-DTPA)-enhanced hepatic MR imaging? J Magn Reson Imaging 32:334–340PubMed
28.
Tanimoto A, Higuchi N, Ueno A (2012) Reduction of ringing artifacts in the arterial phase of gadoxetic acid-enhanced dynamic MR imaging. Magn Reson Med Sci 11:91–97PubMed
29.
Davenport MS, Viglianti BL, Al-Hawary MM et al (2013) Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology 266:452–461PubMed
30.
Davenport MS, Bashir MR, Pietryga JA, Weber JT, Khalatbari S, Hussain HK (2014) Dose-toxicity relationship of gadoxetate disodium and transient severe respiratory motion artifact. AJR Am J Roentgenol 203:796–802PubMed
31.
Agrawal MD, Spincemaille P, Mennitt KW et al (2013) Improved hepatic arterial phase MRI with 3-second temporal resolution. J Magn Reson Imaging 37:1129–1136PubMed
32.
Kim DH, Choi SH, Byun JH et al (2019) Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma. J Hepatol 71:534–542PubMed
33.
Song JS, Choi EJ, Park EH, Lee JH (2018) Comparison of transient severe motion in gadoxetate disodium and gadopentetate dimeglumine-enhanced MRI: effect of modified breath-holding method. Eur Radiol 28:1132–1139PubMed
34.
Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR (2014) Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition. Radiology 271:426–434PubMed
35.
Bashir MR, Husarik DB, Ziemlewicz TJ, Gupta RT, Boll DT, Merkle EM (2012) Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions? J Magn Reson Imaging 35:611–616PubMed
36.
Haradome H, Grazioli L, Al Manea K et al (2012) Gadoxetic acid disodium-enhanced hepatocyte phase MRI: can increasing the flip angle improve focal liver lesion detection? J Magn Reson Imaging 35:132–139PubMed
37.
Gupta RT, Marin D, Boll DT et al (2012) Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium. Eur J Radiol 81:2457–2462PubMed
38.
Doo KW, Lee CH, Choi JW, Lee J, Kim KA, Park CM (2009) “Pseudo washout” sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. AJR Am J Roentgenol 193:W490–W496PubMed
39.
Tateyama A, Fukukura Y, Takumi K, Shindo T, Kumagae Y, Nakamura F (2016) Hepatic hemangiomas: factors associated with pseudo washout sign on Gd-EOB-DTPA-enhanced MR imaging. Magn Reson Med Sci 15:73–82PubMed
40.
Kang Y, Lee JM, Kim SH, Han JK, Choi BI (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 264:751–760PubMed
41.
Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH (2019) LI-RADS version 2017 versus version 2018: diagnosis of hepatocellular carcinoma on gadoxetate disodium-enhanced MRI. Radiology 292:655–663PubMed
42.
Nassif A, Jia J, Keiser M et al (2012) Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging. Radiology 264:741–750PubMed
43.
Leonhardt M, Keiser M, Oswald S et al (2010) Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 38:1024–1028PubMed
44.
Jia J, Puls D, Oswald S et al (2014) Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. Invest Radiol 49:78–86PubMed
45.
Abe T, Kakyo M, Tokui T et al (1999) Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274:17159–17163PubMed
46.
Konig J, Cui Y, Nies AT, Keppler D (2000) Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275:23161–23168PubMed
47.
Ieiri I, Higuchi S, Sugiyama Y (2009) Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703–729PubMed
48.
Benness G, Khangure M, Morris I et al (1996) Hepatic kinetics and magnetic resonance imaging of gadolinium-EOB-DTPA in dogs. Invest Radiol 31:211–217PubMed
49.
Grazioli L, Bondioni MP, Haradome H et al (2012) Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 262:520–529PubMed
50.
Yoneda N, Matsui O, Kitao A et al (2012) Hepatocyte transporter expression in FNH and FNH-like nodule: correlation with signal intensity on gadoxetic acid enhanced magnetic resonance images. Jpn J Radiol 30:499–508PubMed
51.
An HS, Park HS, Kim YJ, Jung SI, Jeon HJ (2013) Focal nodular hyperplasia: characterisation at gadoxetic acid-enhanced MRI and diffusion-weighted MRI. Br J Radiol 86:20130299PubMedPubMedCentral
52.
Fujiwara H, Sekine S, Onaya H, Shimada K, Mikata R, Arai Y (2011) Ring-like enhancement of focal nodular hyperplasia with hepatobiliary-phase Gd-EOB-DTPA-enhanced magnetic resonance imaging: radiological-pathological correlation. Jpn J Radiol 29:739–743PubMed
53.
Kitao A, Matsui O, Yoneda N et al (2018) Differentiation between hepatocellular carcinoma showing hyperintensity on the hepatobiliary phase of gadoxetic acid-enhanced MRI and focal nodular hyperplasia by CT and MRI. AJR Am J Roentgenol 211:347–357PubMed
54.
Bioulac-Sage P, Laumonier H, Couchy G et al (2009) Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 50:481–489PubMed
55.
Ba-Ssalamah A, Antunes C, Feier D et al (2015) Morphologic and molecular features of hepatocellular adenoma with gadoxetic acid-enhanced MR imaging. Radiology 277:104–113PubMed
56.
Fukusato T, Soejima Y, Kondo F et al (2015) Preserved or enhanced OATP1B3 expression in hepatocellular adenoma subtypes with nuclear accumulation of beta-catenin. Hepatol Res 45:E32–E42PubMed
57.
Sekine S, Ogawa R, Ojima H, Kanai Y (2011) Expression of SLCO1B3 is associated with intratumoral cholestasis and CTNNB1 mutations in hepatocellular carcinoma. Cancer Sci 102:1742–1747PubMed
58.
Matsui O, Kadoya M, Kameyama T et al (1991) Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 178:493–497PubMed
59.
Hayashi M, Matsui O, Ueda K et al (1999) Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR Am J Roentgenol 172:969–976PubMed
60.
Matsui O, Kobayashi S, Sanada J et al (2011) Hepatocellular nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 36:264–272PubMedPubMedCentral
61.
Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750PubMed
62.
Toyoda H, Kumada T, Tada T et al (2013) Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. J Hepatol 58:1174–1180PubMed
63.
64.
Kobayashi S, Matsui O, Gabata T et al (2012) Intranodular signal intensity analysis of hypovascular high-risk borderline lesions of HCC that illustrate multi-step hepatocarcinogenesis within the nodule on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 81:3839–3845PubMed
65.
Cannella R, Calandra A, Cabibbo G, Midiri M, Tang A, Brancatelli G (2019) Hyperintense nodule-in-nodule on hepatobiliary phase arising within hypovascular hypointense nodule: outcome and rate of hypervascular transformation. Eur J Radiol 120:108689PubMed
66.
Yoneda N, Matsui O, Kitao A et al (2013) Hypervascular hepatocellular carcinomas showing hyperintensity on hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging: a possible subtype with mature hepatocyte nature. Jpn J Radiol 31:480–490PubMed
67.
Monga SP (2015) β-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology 148:1294–1310PubMedPubMedCentral
68.
Miyoshi Y, Iwao K, Nagasawa Y et al (1998) Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 58:2524–2527PubMed
69.
de La Coste A, Romagnolo B, Billuart P et al (1998) Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 95:8847–8851PubMedCentral
70.
Hoshida Y, Nijman SM, Kobayashi M et al (2009) Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69:7385–7392PubMedPubMedCentral
71.
Kitao A, Matsui O, Yoneda N et al (2015) Hepatocellular carcinoma with beta-catenin mutation: imaging and pathologic characteristics. Radiology 275:708–717PubMed
72.
Trauner M, Halilbasic E (2011) Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 140(1120–1125):e1121–e1112
73.
Wang X, Kiyokawa H, Dennewitz MB, Costa RH (2002) The Forkhead box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc Natl Acad Sci U S A 99:16881–16886PubMedPubMedCentral
74.
Crestani M, De Fabiani E, Caruso D et al (2004) LXR (liver X receptor) and HNF-4 (hepatocyte nuclear factor-4): key regulators in reverse cholesterol transport. Biochem Soc Trans 32:92–96PubMed
75.
Halilbasic E, Claudel T, Trauner M (2013) Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol 58:155–168PubMedPubMedCentral
76.
Bonzo JA, Ferry CH, Matsubara T, Kim JH, Gonzalez FJ (2012) Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4alpha in adult mice. J Biol Chem 287:7345–7356PubMedPubMedCentral
77.
Ning BF, Ding J, Yin C et al (2010) Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. Cancer Res 70:7640–7651PubMed
78.
Hatziapostolou M, Polytarchou C, Aggelidou E et al (2011) An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 147:1233–1247PubMedPubMedCentral
79.
Kitao A, Matsui O, Yoneda N et al (2018) Gadoxetic acid-enhanced magnetic resonance imaging reflects co-activation of beta-catenin and hepatocyte nuclear factor 4alpha in hepatocellular carcinoma. Hepatol Res 48:205–216PubMed
80.
Colletti M, Cicchini C, Conigliaro A et al (2009) Convergence of Wnt signaling on the HNF4alpha-driven transcription in controlling liver zonation. Gastroenterology 137:660–672PubMed
81.
Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680
82.
Metadaten
Titel
Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic background
verfasst von
Azusa Kitao
Osamu Matsui
Norihide Yoneda
Kazuto Kozaka
Satoshi Kobayashi
Wataru Koda
Dai Inoue
Takahiro Ogi
Kotaro Yoshida
Toshifumi Gabata
Publikationsdatum
16.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 6/2020
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-020-06687-y

Weitere Artikel der Ausgabe 6/2020

European Radiology 6/2020 Zur Ausgabe

Oncology

The added value of pelvic surveillance by MRI during postoperative follow-up of rectal cancer, with a focus on abbreviated MRI

Hepatobiliary-Pancreas

Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation?

Imaging Informatics and Artificial Intelligence

Prognostic value of anthropometric measures extracted from whole-body CT using deep learning in patients with non-small-cell lung cancer

Chest

Mucus plugs and bronchial wall thickening on three-dimensional computed tomography in patients with unexplained chronic cough whose sputum yielded filamentous Basidiomycetes

Correction

Correction to: Immediate and delayed hypersensitivity after intra-arterial injection of iodinated contrast media: a prospective study in patients with coronary angiography

Cardiac

Vessel-specific coronary perfusion territories using a CT angiogram with a minimum cost path technique and its direct comparison to the American Heart Association 17-segment model

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

S3-Leitlinie zu Pankreaskrebs aktualisiert

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

13.04.2024 | Klinik aktuell | Kongressbericht | Nachrichten

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet
weitere anzeigen

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen